Newsfeed

Supernus Receives $2 Million for United Therapeutics’ Launch of Orenitram
United Therapeutics Corporation paid Supernus Pharmaceuticals a $2 million milestone payment for the launch of United’s Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in the United States. A form of pulmonary hypertension, PAH is caused by the abnormal functioning of pulmonary artetires, which carry blood from the heart to the lungs. Although it has no cure, there are several treatment options, all …
Poorer Patients Present with More Advanced Pulmonary Hypertension
ATS 2014, SAN DIEGO ─ Pulmonary hypertension patients from lower socioeconomic groups present for initial evaluation at a more advanced disease state than those from higher income groups, according to a new study presented at the 2014 American Thoracic Society International Conference. "Lower socioeconomic status is associated with reduced access to health care and negative effects on health status, but data on its effects on the care of patie…
Pickering family raises awareness of rare lung disease
PICKERING -- A Pickering family is trying to raise awareness of pulmonary hypertension, a rare and potentially fatal lung disease. Isabelle Platnar, 8, was diagnosed with the disease at nine months old and requires supplementary oxygen at all times. When Isabelle Platnar rides her bike, her mom has to run behind her with an oxygen tank. The local eight-year-old has struggled with a rare lung disease since she was a baby and must been hooked up…
Higher BMI is associated with lower mortality risk in patients with severe PH
In patients with congestive heart failure, obesity and a larger waist size have paradoxically been associated with a better prognosis in the prior investigations. This effect, known as the obesity paradox phenomenon, is now being demonstrated in patients with severe pulmonary hypertension. "Obesity-related illnesses, particularly obesity hypoventilation syndrome and sleep apnea, may play a role in the development of pulmonary hypertension, …
Patients with low pulmonary vascular resistance may benefit from complex procedure for PH
Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers. The study was presented at the 2014 American Thoracic Society International Conference. UCSD pioneered PTE in the 1970s for patients who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). …
Underdiagnosed lung disease leaves victims short of breath
It can be an invisible killer. A rare and potentially fatal lung disease sharing symptoms with so many common ailments, it can often fool the very medical specialists who are trained to recognize it. There is no cure, and in the most severe cases -- if left undetected and untreated -- the patient could be dead within an average of two to three years. About 5,000 Canadians have already been diagnosed with pulmonary hypertension (PH) -- wh…
PAH risk factors identified for systemic sclerosis patients
medwireNews: Researchers have identified clinical features that could help predict which patients with systemic sclerosis (SSc) are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment. They found that SSc-related PAH was more likely to develop in patients who had a low diffusion capacity for carbon monoxide (DLco; 1.6), an echocardiogram systolic pulmonary arterial pressure (sPAP) ab…
CANADIANS WITH PULMONARY HYPERTENSION FACE SERIOUS HEALTH, SOCIAL AND FINANCIAL IMPACTS: NEW SURVEY
“Invisibility” of the disease, delays in diagnosis and physical, social and financial burdens among top challenges to be addressed TORONTO, ON. (May 5, 2013) – Results released today from the Pulmonary Hypertension Association (PHA) of Canada’s Patient and Caregiver Survey reveal that Canadians with pulmonary hypertension (PH) are struggling to live with the social, physical and financial burdens the disease places on their lives. Respondents …
New treatment option for PAH now available in Canada
Media Release NEW TREATMENT OPTION FOR PULMONARY ARTERIAL HYPERTENSION NOW AVAILABLE IN CANADA  For the first time, an oral treatment for pulmonary arterial hypertension has shown long term reduction in morbidity events. LAVAL, QC – May 1, 2014 – Actelion Pharmaceuticals Canada Inc. announced today that OPSUMIT® (macitentan) is now commercially available to Canadians affected by pulmonary arterial hypertension (PAH). This new 10 mg once-daily…
Québec First Province to List Adempas® for the Treatment of CTEPH
MONTREAL, April 24, 2014 /CNW/ - Bayer Inc. announced today the Québec public formulary, Régie de l'assurance maladie du Québec (RAMQ), has listed Adempas® (riociguat) for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are inoperable or have persistent or recurrent CTEPH after surgical treatment. Québec is the first province to provide public access to Adempas® for this rare heart and lung disease. Adempas® was added a…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png